Endocrine I Flashcards
tx strategy DM I
low carb diet
insulin replacement
tx strategy DM II
diet modify, exercise
tx gestational DM
dietary mod, exercise, insulin replacement of lifestyle mod fails
aspart
fast acting insulin
glulisine
fast acting insulin
lispro
fast acting insulin
regular insulin
short acting
postprandial glucose control
rapid acting
NPH
intermediate acting insulin
detemir
long acting insulin
glargine
long acting insulin
metformin
biguanide
biguanide MOA
decreased gluconeogenesis
increased glycolysis
increased peripheral glucose uptake (insulin sens)
first like therapy DM II
metformin
adverse metformin
GI upset
lactic acidosis - CI in renal insufficiency
insulin receptor
tyrosine kinase activity
liver - increase glucose stored as glycogen
muscle - increased glycogen and protein synthesis
fat - increased TG storage
chlorpropamide
first gen sulfonylurea
tolbutamide
first gen sulfonylurea
glumepriride
second gen sulfonylurea
glipizide
second gen sulfonylurea
glyburide
second gen sulfonylurea
sulfonylurea MOA
close K channel in beta cell membrane - cell depolarize
-result in insulin release - increased Ca influx
stimulate endogenous insulin in DM II
sulfonylurea
require islet function - useless DM I
adverse sulfonylurea
hypoglycemia
pioglitazone
glitazone/thiazolidinedione
glitazone/thiazolidinedione MOA
increased insulin sensitivity in peripheral tissue
binds PPAR-gamma nuclear transcription regulator
rosiglutazone
glitazone/thiazolidinedione
adverse glitazone/thiazolidinedione
weight gain
edema
hepatotoxic
increased risk of fracture
exenatide
GLP-1 analog
liraglutide
GLP-1 analog
GLP-1 analog MOA
insulin increase
decreased glucagon
adverse GLP-1 analog
N/V
pancreatitis
linagliptin
DPP-4 inhibitor
saxagliptin
DPP-4 inhibitor
sitagliptin
DPP-4 inhibitor
DPP-4 inhibitor MOA
increase insulin
decreased glucagon
adverse DPP-4 inhibitor
UTI
resp infection
pramlintide
amylin analog
MOA amylin analog
decreased gastricy emptying
decreased glucagon
adverse pramlintide
hypoglycemia, nausea, diarrhea
canagliflozin
SGLT-2 inhibitor
MOA canagliflozin
block reabsorption glucose in PCT
inhibitor of SGLT-2
adverse canagliflozin
glucosuria, UTI, vaginal yeast infection
acarbose
a-glucosidase inhibitor
miglitol
a-glucosiase inhibitor
a-glucosidase inhibitor MOA
inhibit intestinal brush border a-glucosidase
-delayed carb hydrolysis and glucose absorption
decreased postprandial hyperglycemia
adverse a-glucosidase inhibitor
GI disturbances
activation of PPAR-gamma
increase insulin sensitivity and levels of adiponectin